Last reviewed · How we verify
colimycin — Competitive Intelligence Brief
phase 1
Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
colimycin (colimycin) — Poitiers University Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| colimycin TARGET | colimycin | Poitiers University Hospital | phase 1 | Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). colimycin — Competitive Intelligence Brief. https://druglandscape.com/ci/colimycin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing